PANCREATIC ADENOCARCINOMA
Clinical trials for PANCREATIC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for PANCREATIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for hard-to-treat cancers with missing MTAP gene
Disease control Not yet recruitingThis early-phase study tests a new drug called CS08399 in people with advanced solid tumors or lymphoma that have a missing MTAP gene. The main goals are to find a safe dose and see how the drug works in the body. About 186 adults will take part, and the study will also check if …
Matched conditions: PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated May 26, 2026 03:23 UTC
-
Engineered immune cells take aim at Hard-to-Treat KRAS cancers
Disease control Not yet recruitingThis early-phase study tests a new treatment called TCR1188-ABC for people with certain advanced cancers (pancreatic, colorectal, lung, or bile duct) that have a specific genetic change called KRAS G12V. The treatment uses a patient's own immune cells, modified in a lab to better…
Matched conditions: PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated May 26, 2026 03:16 UTC
-
New surgical order may boost pancreatic cancer survival
Disease control Not yet recruitingThis study compares a newer surgical technique, called the artery-first approach, with the standard Whipple procedure for pancreatic head cancer. The goal is to see if starting the surgery by exposing a major artery helps surgeons remove the tumor more completely and lowers the c…
Matched conditions: PANCREATIC ADENOCARCINOMA
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated May 26, 2026 03:14 UTC
-
New drug targets hard-to-treat pancreatic cancer in patients with BRCA mutations
Disease control Not yet recruitingThis study tests a drug called lorigerlimab in 40 people with advanced pancreatic cancer that has a specific genetic change (BRCA or related genes). The goal is to see if the drug can shrink tumors. Participants must have tried other treatments first. The study is not yet recruit…
Matched conditions: PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Peter Hosein, MD • Aim: Disease control
Last updated May 26, 2026 03:06 UTC
-
New drug duo takes on hard-to-treat cancers
Disease control Not yet recruitingThis early-phase study tests a combination of two drugs, L19IL2 and ruxolitinib, in people with advanced kidney, pancreatic, or colorectal cancers that have stopped responding to standard treatments. The main goal is to find a safe dose and check for side effects. About 96 partic…
Matched conditions: PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Philogen S.p.A. • Aim: Disease control
Last updated May 26, 2026 03:06 UTC
-
New combo therapy targets tough pancreatic tumors
Disease control Not yet recruitingThis early-phase trial tests whether combining targeted radiation (SBRT) with an experimental immunotherapy called PCX12 is safe for people with locally advanced pancreatic cancer. About 24 participants who have already had chemotherapy will receive the radiation followed by inje…
Matched conditions: PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Haoming (Carl) Qiu • Aim: Disease control
Last updated May 18, 2026 12:10 UTC